S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   458.19 (-0.40%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,664.42 (+2.68%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   458.19 (-0.40%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,664.42 (+2.68%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   458.19 (-0.40%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,664.42 (+2.68%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   458.19 (-0.40%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,664.42 (+2.68%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
Log in

NASDAQ:ACSTAcasti Pharma Stock Price, Forecast & News

$0.74
-0.02 (-2.63 %)
(As of 08/14/2020 09:54 AM ET)
Add
Compare
Today's Range
$0.74
Now: $0.74
$0.75
50-Day Range
$0.47
MA: $0.68
$0.81
52-Week Range
$0.25
Now: $0.74
$3.08
Volume6,600 shs
Average Volume2.92 million shs
Market Capitalization$67.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACST
CUSIPN/A
Phone45-0687-2262

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.14 per share

Profitability

Net Income$-25,510,000.00

Miscellaneous

Employees28
Market Cap$67.73 million
Next Earnings DateN/A
OptionableNot Optionable
$0.74
-0.02 (-2.63 %)
(As of 08/14/2020 09:54 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

How has Acasti Pharma's stock been impacted by COVID-19?

Acasti Pharma's stock was trading at $0.3849 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACST stock has increased by 94.8% and is now trading at $0.7499.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Acasti Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Acasti Pharma
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc (NASDAQ:ACST) released its quarterly earnings results on Monday, June, 29th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.04.
View Acasti Pharma's earnings history
.

What price target have analysts set for ACST?

5 equities research analysts have issued twelve-month price targets for Acasti Pharma's shares. Their forecasts range from $1.40 to $7.00. On average, they expect Acasti Pharma's share price to reach $3.11 in the next year. This suggests a possible upside of 314.7% from the stock's current price.
View analysts' price targets for Acasti Pharma
.

What are Wall Street analysts saying about Acasti Pharma stock?

Here are some recent quotes from research analysts about Acasti Pharma stock:
  • 1. According to Zacks Investment Research, "Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada. " (7/31/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $6/share is based on an equally weighted composite of: (a) $4.96/share, as a 25x multiple of taxed and diluted 2030 EPS of $1.23 discounted back to FY 2020 at 20%; and (b) an NPV discounted cash flow between FY 2020-2030 of $6.32/share, with a discount rate of 13% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/15/2019)

Has Acasti Pharma been receiving favorable news coverage?

Headlines about ACST stock have been trending positive on Friday, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acasti Pharma earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Acasti Pharma
.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 381,500 shares, an increase of 81.2% from the May 31st total of 210,500 shares. Based on an average trading volume of 2,040,000 shares, the short-interest ratio is presently 0.2 days. Currently, 0.5% of the shares of the company are short sold.
View Acasti Pharma's Short Interest
.

Who are some of Acasti Pharma's key competitors?

What other stocks do shareholders of Acasti Pharma own?

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:
  • Ms. Janelle D' Alvise, Pres, CEO, Corp. Sec. & Director
  • Dr. Pierre Lemieux, Co-Founder and COO & Chief Scientific Officer
  • Mr. Jean-François Boily, VP of Fin.
  • Mr. Brian James Groch, Chief Commercial Officer (Age 53)

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

Who are Acasti Pharma's major shareholders?

Acasti Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.28%).
View institutional ownership trends for Acasti Pharma
.

Which major investors are buying Acasti Pharma stock?

ACST stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Acasti Pharma
.

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.75.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of $68.64 million. The biopharmaceutical company earns $-25,510,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Acasti Pharma employs 28 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3. The biopharmaceutical company can be reached via phone at 45-0687-2262 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.